Title |
Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors
|
---|---|
Published in |
Molecular Diagnosis & Therapy, January 2013
|
DOI | 10.1007/s40291-013-0018-7 |
Pubmed ID | |
Authors |
Piotr Rutkowski, Joanna Przybył, Marcin Zdzienicki |
Abstract |
On the basis of the recently published results of a clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the US Food and Drug Administration and the European Medicines Agency have updated their recommendations and approved 36 months of imatinib treatment in patients with v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT)-positive GISTs (also known as CD117-positive GISTs) at high risk of recurrence after surgical resection of a primary tumor. This article discusses patient selection criteria for extended adjuvant therapy with imatinib, different classifications of risk of recurrence, and assessment of the response to therapy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Luxembourg | 1 | 5% |
Unknown | 18 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 21% |
Student > Doctoral Student | 3 | 16% |
Student > Bachelor | 3 | 16% |
Student > Ph. D. Student | 2 | 11% |
Professor | 1 | 5% |
Other | 2 | 11% |
Unknown | 4 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 42% |
Agricultural and Biological Sciences | 2 | 11% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Business, Management and Accounting | 1 | 5% |
Social Sciences | 1 | 5% |
Other | 1 | 5% |
Unknown | 5 | 26% |